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The Canadian Association of Radiologists Guidelines for the Prevention
of Contrast-induced Nephropathy: A Critical Appraisal
Luigi Lepanto, MD*, An Tang, MD, Jessica Murphy-Lavallee, MD, Jean-Sebastien Billiard, MD
Department of Radiology, Centre Hospitalier de l’Universite de Montreal, Montreal, Quebec, CanadaAbstractObjective: The purpose of this study is to critically appraise the Canadian Association of Radiologists (CAR) guidelines on the prevention of
contrast-induced nephropathy (CIN).
Methods: The Appraisal of Guidelines Research and Evaluation (AGREE) tool is a questionnaire that consists of 23 key items organized in 6
domains (scope and purpose, stakeholder involvement, rigor of development, clarity and presentation, applicability, editorial independence).
Four radiologists read the guidelines and completed the questionnaire independently. To assess the quality of the evidence, the articles listed
in the bibliography were reviewed, and the following data were collected and tabulated: the type of contrast, the administration route, and the
level of evidence (Centre for Evidence Based Medicine, University of Oxford).
Results: The highest score was for scope and purpose (92%), whereas the lowest scores were for rigor of development (50%) and applicability
(40%). The score for the remaining domains were the following: stakeholder involvement (59%), clarity and presentation (69%), and editorial
independence (63%). Although the bibliography of the CAR guidelines list 46 articles, only 33 were deemed pertinent to support the
recommendations related to risk stratification or risk reduction of CIN. Only 3 articles dealt specifically with intravenous injection of iodinated
contrast. Four articles dealt with ionic contrast, and, in 17 references, the contrast type was not specified. The best evidence (level 1) was in
support of risk-reduction recommendations, but, in 8 of the 9 articles cited, the route of administration studied was exclusively intra-arterial.
Conclusion: It would be appropriate to revisit the topic of CIN and formulate new guidelines. A formal systematic review of the literature
should be undertaken and the data extraction should specifically address contrast type and route of administration, as well as the applicability
of any recommendations.ResumeObjectif: L’etude visait a` evaluer de fac¸on critique les lignes directrices de l’Association canadienne des radiologistes (CAR) pour la
prevention de la nephropathie aux produits de contraste (NPC).
Methodes: La grille AGREE (Appraisal of Guidelines Research and Evaluation) consiste en un questionnaire comprenant 23 crite`res organises
en six domaines (champ et objectifs, participation des groupes concernes, rigueur d’elaboration, clarte et presentation, applicabilite et
independance editoriale). Quatre radiologistes ont lu les lignes directrices et rempli le questionnaire de fac¸on independante. Pour evaluer la
qualite des preuves utilisees, les articles de la bibliographie ont fait l’objet d’un examen et les donnees suivantes ont ete recueillies et totalisees:
le type de produit de contraste, la voie d’administration et le niveau de preuve (Centre for Evidence Based Medicine, Universite d’Oxford).
Resultats: Le score le plus eleve a ete obtenu pour la dimension champ et objectifs (92%), tandis que les scores les plus bas ont ete
enregistres pour la rigueur d’elaboration (50%) et l’applicabilite (40%). Les scores obtenus dans les autres domaines sont les suivants:
participation des groupes concernes, 59%; clarte et presentation, 69%; independance editoriale, 63%. Bien que la bibliographie des lignes
directrices de la CAR compte 46 articles, seuls 33 d’entre eux ont ete juges pertinents pour appuyer les recommandations relatives a` la
stratification ou a` la reduction du risque de NPC. Seulement trois articles traitaient specifiquement de l’injection intraveineuse de produits de
contraste iodes. Quatre articles traitaient des produits de contraste ioniques, tandis que 17 des articles cites ne precisaient pas le type de
produit de contraste utilise. Le niveau de preuve le plus eleve (niveau 1) provient des references liees aux recommandations visant la
reduction du risque, mais huit des neuf articles cites ne portaient que sur l’administration par voie intra-arterielle.
Conclusion: Il serait opportun de revenir sur la NPC et de formuler de nouvelles lignes directrices. Un examen systematique formel de la
documentation devrait eˆtre entrepris. Le processus d’extraction des donnees devrait s’attarder specifiquement au type de produit de contraste* Address for correspondence: Luigi Lepanto, MD, Department of Radiology, Centre Hospitalier de l’Universite de Montreal, 1058, St-Denis Street,
Montreal, Quebec H2X 3J4, Canada.
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Introduction critically appraise theCARguidelines on the prevention ofCIN.Clinical guidelines play an important role in the practice of
medicine. Formalized practice guidelines attempt to elevate the
quality ofmedical care by identifying those practices, supported
by evidence, that are in the best interests of the patients. An
important aspect of this process is the appraisal of guidelines on
a regular basis to guarantee that the recommended practices are
in keeping with the evolution of knowledge and to modify the
guidelines accordingly when necessary. Contrast-induced
nephropathy (CIN) has become a topic of intense interest, in
large part because of an ever-increasing number of patients who
receive intravenous injection of iodinated contrast for computed
tomography studies. Because of the risk posed by an ever-
growing number of patients subjected to intravenous contrast
agents, the Canadian Association of Radiologists (CAR)
decided to form a committee charged with developing guide-
lines for practicing radiologists [1]. Appraisal of Guidelines
Research and Evaluation (AGREE) is an international collab-
orationwhose goal is to improve the quality and effectiveness of
clinical practiceguidelinesbyestablishing a framework for their
development, reporting, and assessment. A product of this
collaboration is the development of an appraisal instrument for
assessing the methodological quality of clinical practice
guidelines (The AGREE Collaboration, AGREE Instrument,
www.agreecollaboration.org). Although this tool is a very
useful guide, it doesnot assess the quality of the evidence used to
elaborate the guidelines. The purpose of this study was toTable 1
The Appraisal of Guidelines Research and Evaluation (AGREE) tool for the app
Scope and purpose 1. The overall objective(s) of the
2. The clinical question(s) cover
3. The patients to whom the gui
Stakeholder involvement 4. The guideline development gr
5. The patients’ views and prefe
6. The target users of the guidel
7. The guideline has been pilote
Rigor of development 8. Systematic methods were use
9. The criteria for selecting the e
10. The methods used for formula
11. The health benefits, adverse e
12. There is an explicit link betw
13. The guideline has been extern
14. A procedure for updating the
Clarity and presentation 15. The recommendations are spe
16. The different options for man
17. Key recommendations are eas
18. The guideline is supported wi
Applicability 19. The potential organizational b
20. The potential cost implication
21. The guideline presents key re
Editorial independence 22. The guideline is editorially in
23. Conflicts of interest of guidelThiswill be done in 2 steps: first, the AGREE appraisal tool will
be applied to assess the guidelines, and second, the bibliography
submitted as evidence within the guidelines will be appraised.
Methods
The AGREE tool is a questionnaire that consists of 23 key
items organized into 6 domains (Table 1). Each domain is
intended to capture a separate dimension of guideline quality.
The 6 domains are the following: scope and purpose,
stakeholder involvement, rigor of development, clarity and
presentation, applicability, and editorial independence. It is
recommended that the appraisal be carried out by at least 2
appraisers and preferably 4. In this case, 4 appraisers
participated in the evaluation (ie, the authors). The appraisers
are radiologists specialized in abdominal imaging, with 5-20
years of experience. Each item is rated on a 4-point scale that
ranges from 4 (‘‘strongly agree’’) to 1 (‘‘strongly disagree’’),
with 2 mid points (3 [‘‘agree’’] and 2 [‘‘disagree’’]). The
scale measures the extent to which a criterion (item) has been
fulfilled. For each item, there is the opportunity for an
appraiser to include comments. Domain scores can be
calculated by summing up all the scores of the individual
items in a domain and by standardizing the total as
a percentage of the maximum possible score for that domain.
The 4 appraisers were instructed to read the guidelines
thoroughly. They were then instructed to complete the AGREEraisal of clinical practice guidelines
guideline is (are) specifically described.
ed by the guideline is (are) specifically described.
deline is meant to apply are specifically described.
oup includes individuals from all the relevant professional groups.
rences have been sought.
ine are clearly defined.
d among end users.
d to search for evidence.
vidence are clearly described.
ting the recommendations are clearly described.
ffects, and risks have been considered in formulating the recommendations.
een the recommendations and the supporting evidence.
ally reviewed by experts before its publication.
guideline is provided.
cific and unambiguous.
agement of the condition are clearly presented.
ily identifiable.
th tools for application.
arriers in applying the recommendations have been discussed.
s of applying the recommendations have been considered.
view criteria for monitoring and/or audit purposes.
dependent from the funding body.
ine development members have been recorded.
Table 2
Appraisal of Guidelines Research and Evaluation (AGREE) tool applied to
the Canadian Association of Radiologists (CAR) guidelines for the
prevention of contrast-induced nephropathy
Item
Appraiser
1
Appraiser
2
Appraiser
3
Appraiser
4
Domain
score, %
Scope and
purpose
1 4 3 4 4
2 4 3 4 4
3 4 2 4 4 92
Stakeholder
involvement
4 3 4 4 3
5 1 1 1 1
6 4 3 4 3
7 1 3 1 1 59
Rigor of
development
8 2 2 3 2
9 1 2 1 1
10 1 2 2 2
11 2 3 4 4
12 3 4 4 3
13 1 1 1 1
14 1 1 1 1 50
Clarity and
presentation
15 3 2 3 3
16 4 4 4 4
17 4 3 4 4
18 4 1 3 1 69
Applicability 19 1 2 4 1
20 1 1 1 1
21 1 2 3 1 40
Editorial
independence
22 4 4 3 4
23 1 1 2 1 63
Table 3
Route of contrast administration: articles referenced in the Canadian Asso-
ciation of Radiologists (CAR) guidelines on contrast-induced nephropathy
Route of administration
Intravenous Intra-arterial Either Not specified
Risk stratification
references
11,16 3,4,6e9,12e14 1,2,5 10,15,17
Risk reduction
references
19 21,22,25,27,
28,30,31,33
23 18,20,24,26,
29,32
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assess the different items. The appraisals were conducted inde-
pendently, and the final results were collated by 1 of the authors.
To assess the quality of the evidence, the articles listed in the
bibliography were reviewed, and the following data were
collected and tabulated: (1) the type of contrast used; (2) the
administration route of the contrast; and (3) the level of
evidence (Centre for Evidence Based Medicine, University of
Oxford). The articles were subdivided into 2 groups by 1 of the
authors. The articles in the first group were referenced in the
guidelines to support recommendations on risk identification
and stratification [2e18]. The second group of articles sup-
ported recommendations on risk reduction (ie, fluid adminis-
tration, choice of contrast, and pharmacologic prevention)
[19e34]. Each article was assessed by 1 of 3 authors, and
the results were tabulated by the remaining author.
Results
The scores from each appraiser for each of the 23 items
evaluated are summarized in Table 2. The overall score for
each domain is also shown, expressed as a percentage of the
maximum possible score. The highest score was given for the
description of scope and purpose (score, 92%). The clinical
question and the objectives of the guidelines were clearly
stated. With regard to stakeholder involvement (score, 59%),
the weakest aspects related to the absence of any evaluation of
patients’ views and preferences, as well as the absence of
a pilot program to evaluate the guidelines before general
dissemination. The score for rigor of development was 50%.
As stated in the methodology of the guidelines document, 2 of
the authors used the existing guidelines in a number of radi-
ology departments from 5 Canadian cities as a starting point,
and, after an in-depth literature search with critical review,
a consensus document was drawn up. This working document
then was discussed by a panel, and a final consensus document
was produced. Although the terms in-depth search and critical
review are used, there is no explicit description of the literature
review process. No formal methodology is described, and no
external review process was described in validating the
guidelines. No procedure is proposed in the document for
updating the guidelines.Where explicit references are used, an
explicit link was made between recommendation and sup-
porting evidence. The score for clarity and presentation was
69%. The AGREE document suggests the distribution of tools
(eg, forms) to aid in the application of the guidelines; although
clear tables and algorithms are provided in the guidelines
document, no addition material is available. The lowest score
was assigned for applicability (score, 40%). The logistics of
dealing with patients in the context of outpatient examinations
for computed tomography with intravenous infusion, in the
view of the appraisers, was not adequately assessed. Also,
a clear distinctionwas notmade between intravenous and intra-
arterial injection of iodinated contrast, both in terms of the
pertinence of the supporting evidence and the application of
the guidelines. Editorial independence received a score of 63%
only because no specific mention is made of the possibility orabsence of potential conflicts of interest. There is no reason to
believe, however, that conflicts of interest were present.
The results of the appraisal of the pertinent articles cited
in the text of the guidelines are summarized in Tables 3e5.
Although the bibliography of the CAR guidelines lists 46
articles, only 33 were deemed pertinent to support the
recommendations related to risk stratification or risk reduc-
tion of CIN. With regard to the route of contrast adminis-
tration (Table 3), only 3 articles deal specifically with
intravenous injection of iodinated contrast, whereas 17 arti-
cles report findings after intra-arterial injection. In 9 articles,
the route of administration is not specified. Some of these
articles, as well as those that reported on patients having
received either intravenous or intra-arterial injections, are
review articles or expert opinions. With regard to contrast
type (Table 4), 4 articles deal with ionic contrast, and, in 17
Table 4
Contrast type: articles referenced in the Canadian Association of Radiolo-
gists (CAR) guidelines on contrast-induced nephropathy
Contrast type
Ionic Nonionic Either Not specified
Risk
stratification
3,6 4,9,16 8,14 1,2,5,7,10e13,15,17
Risk
reduction
21,25 22,23,27,28,30,31,33 18e20,24,26,29,32
Table 5
Levels of evidence (Centre for Evidence Based Medicine, University of
Oxford): articles referenced in the Canadian Association of Radiologists
(CAR) guidelines on contrast-induced nephropathy
Levels of evidence
1a,b,c 2a,b,c 3a,b,c4 5
Risk
stratification
8 4e7,139 1e3,11,12,14e1710
Risk
reduction
21e23,25,27,
28,30,31,33
18,19 20,24,26,29,32
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evidence (Table 5) is in support of risk-reduction recom-
mendations, with 9 articles assessed as level 1. However, in 8
of these articles, the route of administration studied is
exclusively intra-arterial. In the remaining article, patients
with either intra-arterial or intravenous administration were
studied, but most received contrast by the intra-arterial route.
Discussion
The time and effort put into establishing clinical practice
guidelines is often done on a voluntary basis. The authors of
the CAR practice guidelines on CIN are to be commended
for their contribution. The importance of clinical guidelines
has long been recognized and is behind the creation of the
AGREE Collaboration. AGREE is an international collabo-
ration of researchers and policy makers who seek to improve
the quality and effectiveness of clinical practice guidelines
by establishing a shared framework for their development,
reporting, and assessment. The appraisal tool developed by
this collaboration will aid in improving existing guidelines
and guide the formulation of new ones. Assessing the val-
idity of the tool is beyond the scope of this article, but there
is ongoing work by the AGREE Next Steps Consortium to
refine the tool and validate its use. In a recent publication,
researchers evaluated the usefulness of the items in the
appraisal instrument and found that quality ratings of the
AGREE domains were significant predictors of outcome
measures associated with guideline adoption [35,36].
Since the publication of the CAR guidelines on contrast
nephropathy in 2007, several studies and reviews have been
published on the topic. In the radiology literature, some
investigators’ findings raise doubts about the true incidence of
CIN [37,38]. This is based on the observation that creatinine
elevation can be accounted for by the background fluctuation
of kidney function, underlying disease, or treatment. Other
investigators have found that long-term adverse effects are rare
after intravenous administration of contrast agents for
computed tomography studies [39]. Several prospective,
randomized trials that compared the incidence of CIN with
different contrast agents indicate that the incidence is lower
when the route of contrast agent administration is intravenous
rather than intra-arterial [40e44]. The CIN Consensus
Working Panel stated the following: intra-arterial administra-
tion of contrast media may be associated with a greater risk for
CIN above that observedwith intravenous administration [45].With respect to the CAR guidelines on contrast
nephropathy, rigor of development and applicability are the
dimensions that scored the lowest on the appraisal tool.
Evidence-based practice requires that appropriate literature
search and bibliographic research methods be applied in the
evaluation of a specific clinical question. Aside from
reviewing specific randomized controlled trials, systematic
reviews and existing practice guidelines can be consulted.
Our analysis shows that the evidence level of the references
cited in the guidelines document is variable. In the case of
intravenously administered contrast, the supporting evidence
is scarce and poor in quality. The failure to distinguish
between intravenous and intra-arterial injection of contrast
agent is a shortcoming. Although only a few articles in the
bibliography of the guidelines deal with ionic contrast, the
fact that this is rarely if ever used in today’s practice ques-
tions the validity of the evidence used. More importantly, in
a significant number of the references cited, neither the type
of contrast (ionic or nonionic) nor the route of administration
is specified. It is clear that, in a revision of the guidelines,
these must be specifically addressed.
Applicability of any practice guidelines is an important
issue. The logistics involved in screening patients for pre-
disposing factors to renal disease referred for medical
imaging can be quite onerous. The impact on health
professionals and patients alike must be taken into account.
Guidelines that are impractical to apply will, ultimately, be
ignored. A pilot program to study appropriateness in the
clinical context and feasibility are excellent strategies to
avoid difficulties in application of recommended guidelines.
In conclusion, it is important to emphasize that the
purpose of our appraisal is to offer constructive criticism on
a process that must be ongoing. New evidence will always be
produced and must be incorporated within existing guide-
lines. In our view, it would be appropriate to revisit the topic
of CIN and formulate new guidelines. A formal systematic
review of the literature must be undertaken, and the data
extraction should specifically address contrast type and route
of administration, as well as the applicability of any
recommendations.References
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